NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer

Abstract Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Claudia Marchetti, Marco D’Indinosante, Carolina Bottoni, Chiara Di Ilio, Stefano Di Berardino, Barbara Costantini, Angelo Minucci, Laura Vertechy, Giovanni Scambia, Anna Fagotti
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7ac325423fbd40e8b6a886986321c46c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7ac325423fbd40e8b6a886986321c46c
record_format	dspace
spelling	oai:doaj.org-article:7ac325423fbd40e8b6a886986321c46c2021-12-02T14:49:11ZNLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer10.1038/s41598-021-90361-w2045-2322https://doaj.org/article/7ac325423fbd40e8b6a886986321c46c2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90361-whttps://doaj.org/toc/2045-2322Abstract Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. We consecutively enrolled a series of 397 newly diagnosed high-grade serous-advanced OC-patients. All patients were tested for BRCA-mutational-status and blood-parameters have been collected 48 h before staging-surgery. A significant correlation of NLR with disease distribution (p < 0.005) was found and patients with NLR < 4 underwent primary-debulking-surgery more frequently (p-value 0.001), with a lower surgical-complexity-score (p-value 0.002). Regarding survival-data, patients with NLR < 4 had a significant 7-month increase in mPFS (26 vs 19 months, p = 0.009); focusing on the BRCA-status, among both BRCA-mutated and BRCA-wild type patients, those with lower NLR had a significantly prolonged mPFS compared to patients with NLR > 4 (BRCA-mutated: 35 vs 23 months, p = 0.03; BRCA-wt: 19 vs 16 months, p = 0.05). At multivariate-analysis, independent factors of prolonged PFS were BRCA mutational status, having received complete cytoreduction and NLR < 4. Also, the strongest predictors of longer OS were BRCA-mutational status, having received complete cytoreductive surgery, NLR < 4 and age. NLR is confirmed to be a prognostic marker in OC-patients and it seems unrelated with BRCA-mutational status.Claudia MarchettiMarco D’IndinosanteCarolina BottoniChiara Di IlioStefano Di BerardinoBarbara CostantiniAngelo MinucciLaura VertechyGiovanni ScambiaAnna FagottiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Claudia Marchetti Marco D’Indinosante Carolina Bottoni Chiara Di Ilio Stefano Di Berardino Barbara Costantini Angelo Minucci Laura Vertechy Giovanni Scambia Anna Fagotti NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
description	Abstract Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. We consecutively enrolled a series of 397 newly diagnosed high-grade serous-advanced OC-patients. All patients were tested for BRCA-mutational-status and blood-parameters have been collected 48 h before staging-surgery. A significant correlation of NLR with disease distribution (p < 0.005) was found and patients with NLR < 4 underwent primary-debulking-surgery more frequently (p-value 0.001), with a lower surgical-complexity-score (p-value 0.002). Regarding survival-data, patients with NLR < 4 had a significant 7-month increase in mPFS (26 vs 19 months, p = 0.009); focusing on the BRCA-status, among both BRCA-mutated and BRCA-wild type patients, those with lower NLR had a significantly prolonged mPFS compared to patients with NLR > 4 (BRCA-mutated: 35 vs 23 months, p = 0.03; BRCA-wt: 19 vs 16 months, p = 0.05). At multivariate-analysis, independent factors of prolonged PFS were BRCA mutational status, having received complete cytoreduction and NLR < 4. Also, the strongest predictors of longer OS were BRCA-mutational status, having received complete cytoreductive surgery, NLR < 4 and age. NLR is confirmed to be a prognostic marker in OC-patients and it seems unrelated with BRCA-mutational status.
format	article
author	Claudia Marchetti Marco D’Indinosante Carolina Bottoni Chiara Di Ilio Stefano Di Berardino Barbara Costantini Angelo Minucci Laura Vertechy Giovanni Scambia Anna Fagotti
author_facet	Claudia Marchetti Marco D’Indinosante Carolina Bottoni Chiara Di Ilio Stefano Di Berardino Barbara Costantini Angelo Minucci Laura Vertechy Giovanni Scambia Anna Fagotti
author_sort	Claudia Marchetti
title	NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_short	NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_full	NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_fullStr	NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_full_unstemmed	NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
title_sort	nlr and brca mutational status in patients with high grade serous advanced ovarian cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7ac325423fbd40e8b6a886986321c46c
work_keys_str_mv	AT claudiamarchetti nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT marcodindinosante nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT carolinabottoni nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT chiaradiilio nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT stefanodiberardino nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT barbaracostantini nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT angelominucci nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT lauravertechy nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT giovanniscambia nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT annafagotti nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer
_version_	1718389519193997312

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer

Ejemplares similares